Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau)
Álvarez, Rosa (Hospital General Universitario Gregorio Marañón)
Ortega, Ana Laura (Hospital Universitario de Jaén)
de Alda, Lucía Ruiz (Roche Farma)
Gordo, Rocío (Roche Farma)
García, J.Francisco (Roche Farma)
Ivanova-Markova, Yoana (Weber)
González-Domínguez, Almudena (Weber)
San Cristóbal, Raquel Sánchez (Weber)
Rojo, Federico (Hospital Universitario Fundación Jiménez Díaz)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	In recent years, target therapies to specific molecular alterations in advanced non-small cell lung cancer (NSCLC) have been identified and have shown superior efficacy compared to non-targeted treatments. Anaplastic lymphoma kinase (ALK) is one of the therapeutic targets; nevertheless, ALK diagnosis is not performed in all NSCLC patients in Spain. The objective of this study is to estimate in monetary terms the benefit for the Spanish society of ALK diagnosis in advanced NSCLC patients. A cost-benefit analysis of ALK diagnosis vs. non-diagnosis in advanced NSCLC patients was carried out from the Spanish social perspective, with a time horizon of 5 years. Costs, benefits and the cost-benefit ratio were measured. The analysis has considered the overall survival in advanced NSCLC patients treated with the ALK-tyrosine kinase inhibitor (TKI) alectinib. The natural history of NSCLC was simulated using a Markov model. A 3% discount rate was applied to both costs and benefits. The result was tested using a deterministic sensitivity analysis. The cost of ALK diagnosis vs. non-diagnosis in the base case would be €10. 19 million, generating benefits of €11. 71 million. The cost-benefit ratio would be €1. 15. In the sensitivity analysis, the cost-benefit ratio could range from €0. 89 to €2. 10. The results justify the universal application of ALK diagnosis in advanced NSCLC, which generates a benefit for Spanish society that outweighs its costs and allows optimal treatment with targeted therapies for these patients.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	ALK ; Cost-benefit ; Cost-effectiveness ; Economic evaluation ; Lung cancer ; Non-small cell lung cancer
Publicat a:	Global and Regional Health Technology Assessment, Vol. 9 (january 2022) , p. 82-90, ISSN 2283-5733

DOI: 10.33393/GRHTA.2022.2449
PMID: 36628311

9 p, 1.5 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats